Compare · CDXS vs LIN
CDXS vs LIN
Side-by-side comparison of Codexis Inc. (CDXS) and Linde plc (LIN): market cap, price performance, sector, and recent activity on the wire.
Summary
- CDXS operates in Industrials, while LIN operates in Basic Materials - the two are in different parts of the market.
- LIN is the larger of the two at $161.42B, about 1083.9x CDXS ($148.9M).
- LIN has been more active in the news (5 items in the past 4 weeks vs 3 for CDXS).
- LIN has more recent analyst coverage (25 ratings vs 12 for CDXS).
- Company
- Codexis Inc.
- Linde plc
- Price
- -
- -
- Market cap
- $148.9M
- $161.42B
- 1M return
- -
- +8.74%
- 1Y return
- -
- +10.43%
- Industry
- Major Chemicals
- Major Chemicals
- Exchange
- NASDAQ
- NYSE
- IPO
- 2010
- News (4w)
- 3
- 5
- Recent ratings
- 12
- 25
Codexis Inc.
Codexis, Inc. discovers, develops, and sells biocatalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
Linde plc
Linde plc operates as an industrial gas company in North and South America, Europe, the Middle East, Africa, and the Asia Pacific. It offers oxygen, nitrogen, argon, rare gases, carbon dioxide, hydrogen, helium, electronic and specialty gases, acetylene, and carbon monoxide. The company also designs and constructs turnkey process plants, such as olefin, natural gas, air separation, hydrogen and synthesis gas, and other plants. It serves healthcare, petroleum refining, manufacturing, food, beverage carbonation, fiber-optics, steel making, aerospace, electronics, chemical, and water treatment industries. The company was founded in 1879 and is based in Guildford, the United Kingdom.
Latest CDXS
- SEC Form 4 filed by Codexis Inc.
- SEC Form 4 filed by Codexis Inc.
- Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA
- Codexis to Participate in Cantor Global Healthcare Conference 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Codexis Inc.
- SEC Form 10-Q filed by Codexis Inc.
- Codexis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Codexis Reports Second Quarter 2026 Financial Results
- Codexis Appoints David Butler, PhD, to Strategic Advisory Board
- Codexis to Report Second Quarter 2026 Financial Results on August 11
Latest LIN
- Barclays initiated coverage on Linde plc with a new price target
- SEC Form 3 filed by Linde plc
- SEC Form 4 filed by Linde plc
- SEC Form 4 filed by Linde plc
- Linde Announces Third Quarter 2026 Earnings and Conference Call Schedule
- KeyBanc Capital Markets initiated coverage on Linde plc with a new price target
- Director Reynolds Paula Rosput bought $47,912 worth of Ordinary Shares (100 units at $479.12), increasing direct ownership by 14% to 816 units (SEC Form 4)
- SEC Form 10-Q filed by Linde plc
- Linde plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Linde Reports Second-Quarter 2026 Results